BioNexus Gene Lab (BGLC) Total Liabilities (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Total Liabilities data on file, last reported at $946877.0 in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 44.57% year-over-year to $946877.0; the trailing twelve-month figure through Mar 2026 stood at $946877.0 (down 44.57% YoY), and the FY2025 full-year result was $637856.0, down 69.78% from the prior year.
• Total Liabilities improved to $946877.0 in Q1 2026, from $637856.0 in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $2.1 million in Q4 2024 to a low of $637856.0 in Q4 2025.
• A 5-year average of $1.6 million and a median of $1.7 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities climbed 29.33% in 2023 and slumped 69.78% in 2025, its largest moves.
• Tracing BGLC's Total Liabilities over 5 years: stood at $2.1 million in 2022, then declined by 16.06% to $1.7 million in 2023, then rose by 21.19% to $2.1 million in 2024, then tumbled by 69.78% to $637856.0 in 2025, then soared by 48.45% to $946877.0 in 2026.
• Business Quant data shows BGLC's Total Liabilities at $946877.0 in Q1 2026, $637856.0 in Q4 2025, and $804966.0 in Q3 2025.